Body weight as a predictor of antidepressant efficacy in the GENDEP project

Rudolf Uher; Ole Mors; Joanna Hauser; Marcella Rietschel; Wolfgang Maier; Dejan Kozel; Neven Henigsberg; Daniel Souery; Anna Placentino; Nader Perroud; Moica Zvezdana Dernovsek; Jana Strohmaier; Erik Roj Larsen; Astrid Zobel; Anna Leszczynska-Rodziewicz; Petra Kalember; Laura Pedrini; Sylvie Linotte; Cerisse Gunasinghe; Katherine J Aitchison; Peter McGuffin; Anne Farmer

doi:10.1016/j.jad.2009.02.013

Body weight as a predictor of antidepressant efficacy in the GENDEP project

Rudolf Uher, Ole Mors, Joanna Hauser, Marcella Rietschel, Wolfgang Maier, Dejan Kozel, Neven Henigsberg, Daniel Souery, Anna Placentino, Nader Perroud, Moica Zvezdana Dernovsek, Jana Strohmaier, Erik Roj Larsen, Astrid Zobel, Anna Leszczynska-Rodziewicz, Petra Kalember, Laura Pedrini, Sylvie Linotte, Cerisse Gunasinghe, Katherine J AitchisonPeter McGuffin, Anne Farmer

Research output: Contribution to journal › Article › peer-review

79 Citations (Scopus)

Abstract

BACKGROUND: Being overweight or obese may be associated with poor response to antidepressants. The present report explores the moderation of antidepressant response by body weight to establish the specificity to antidepressant mode of action, type of depressive symptoms and gender.

METHODS: Height and weight were measured in 797 men and women with major depression treated with escitalopram or nortriptyline for twelve weeks as part of the Genome Based Therapeutic Drugs for Depression (GENDEP) project. Body mass index (BMI) and obesity (BMI>30) were tested as predictors of change in depressive symptoms using mixed linear models.

RESULTS: Higher BMI and obesity predicted poor response to nortriptyline but did not significantly influence response to escitalopram. The moderation of response by body weight was due to differential improvement in neurovegetative symptoms, including sleep and appetite. The relationship between body weight and change in neurovegetative symptoms was moderated by gender with obese men responding less to nortriptyline and obese women having poorer response to both antidepressants.

LIMITATIONS: As no placebo arm was included, the specificity of findings to antidepressants is relative. Lack of specific measures precluded accounting for differences in body fat distribution.

CONCLUSIONS: Body weight should be considered in the assessment of depression as it may inform the selection of antidepressant treatment.

Original language	English
Pages (from-to)	147 - 154
Number of pages	8
Journal	Journal of Affective Disorders
Volume	118
Issue number	1-3
DOIs	https://doi.org/10.1016/j.jad.2009.02.013
Publication status	Published - Nov 2009

Keywords

Adult
Affect/drug effects
Antidepressive Agents, Second-Generation/adverse effects
Antidepressive Agents, Tricyclic/adverse effects
Appetite/drug effects
Body Mass Index
Body Weight/physiology
Citalopram/adverse effects
Depressive Disorder, Major/drug therapy
Female
Humans
Male
Middle Aged
Nortriptyline/adverse effects
Obesity/physiopathology
Overweight/physiopathology
Sleep/drug effects
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jad.2009.02.013

Cite this

Uher, R., Mors, O., Hauser, J., Rietschel, M., Maier, W., Kozel, D., Henigsberg, N., Souery, D., Placentino, A., Perroud, N., Dernovsek, M. Z., Strohmaier, J., Larsen, E. R., Zobel, A., Leszczynska-Rodziewicz, A., Kalember, P., Pedrini, L., Linotte, S., Gunasinghe, C., ... Farmer, A. (2009). Body weight as a predictor of antidepressant efficacy in the GENDEP project. Journal of Affective Disorders, 118(1-3), 147 - 154. https://doi.org/10.1016/j.jad.2009.02.013

@article{a72d0c9c1d77495baa5b5f55e154f731,

title = "Body weight as a predictor of antidepressant efficacy in the GENDEP project",

abstract = "BACKGROUND: Being overweight or obese may be associated with poor response to antidepressants. The present report explores the moderation of antidepressant response by body weight to establish the specificity to antidepressant mode of action, type of depressive symptoms and gender.METHODS: Height and weight were measured in 797 men and women with major depression treated with escitalopram or nortriptyline for twelve weeks as part of the Genome Based Therapeutic Drugs for Depression (GENDEP) project. Body mass index (BMI) and obesity (BMI>30) were tested as predictors of change in depressive symptoms using mixed linear models.RESULTS: Higher BMI and obesity predicted poor response to nortriptyline but did not significantly influence response to escitalopram. The moderation of response by body weight was due to differential improvement in neurovegetative symptoms, including sleep and appetite. The relationship between body weight and change in neurovegetative symptoms was moderated by gender with obese men responding less to nortriptyline and obese women having poorer response to both antidepressants.LIMITATIONS: As no placebo arm was included, the specificity of findings to antidepressants is relative. Lack of specific measures precluded accounting for differences in body fat distribution.CONCLUSIONS: Body weight should be considered in the assessment of depression as it may inform the selection of antidepressant treatment.",

keywords = "Adult, Affect/drug effects, Antidepressive Agents, Second-Generation/adverse effects, Antidepressive Agents, Tricyclic/adverse effects, Appetite/drug effects, Body Mass Index, Body Weight/physiology, Citalopram/adverse effects, Depressive Disorder, Major/drug therapy, Female, Humans, Male, Middle Aged, Nortriptyline/adverse effects, Obesity/physiopathology, Overweight/physiopathology, Sleep/drug effects, Treatment Outcome",

author = "Rudolf Uher and Ole Mors and Joanna Hauser and Marcella Rietschel and Wolfgang Maier and Dejan Kozel and Neven Henigsberg and Daniel Souery and Anna Placentino and Nader Perroud and Dernovsek, {Moica Zvezdana} and Jana Strohmaier and Larsen, {Erik Roj} and Astrid Zobel and Anna Leszczynska-Rodziewicz and Petra Kalember and Laura Pedrini and Sylvie Linotte and Cerisse Gunasinghe and Aitchison, {Katherine J} and Peter McGuffin and Anne Farmer",

year = "2009",

month = nov,

doi = "10.1016/j.jad.2009.02.013",

language = "English",

volume = "118",

pages = "147 -- 154",

journal = "Journal of Affective Disorders",

issn = "0165-0327",

publisher = "Elsevier",

number = "1-3",

}

Uher, R, Mors, O, Hauser, J, Rietschel, M, Maier, W, Kozel, D, Henigsberg, N, Souery, D, Placentino, A, Perroud, N, Dernovsek, MZ, Strohmaier, J, Larsen, ER, Zobel, A, Leszczynska-Rodziewicz, A, Kalember, P, Pedrini, L, Linotte, S, Gunasinghe, C , Aitchison, KJ , McGuffin, P & Farmer, A 2009, 'Body weight as a predictor of antidepressant efficacy in the GENDEP project', Journal of Affective Disorders, vol. 118, no. 1-3, pp. 147 - 154. https://doi.org/10.1016/j.jad.2009.02.013

TY - JOUR

T1 - Body weight as a predictor of antidepressant efficacy in the GENDEP project

AU - Uher, Rudolf

AU - Mors, Ole

AU - Hauser, Joanna

AU - Rietschel, Marcella

AU - Maier, Wolfgang

AU - Kozel, Dejan

AU - Henigsberg, Neven

AU - Souery, Daniel

AU - Placentino, Anna

AU - Perroud, Nader

AU - Dernovsek, Moica Zvezdana

AU - Strohmaier, Jana

AU - Larsen, Erik Roj

AU - Zobel, Astrid

AU - Leszczynska-Rodziewicz, Anna

AU - Kalember, Petra

AU - Pedrini, Laura

AU - Linotte, Sylvie

AU - Gunasinghe, Cerisse

AU - Aitchison, Katherine J

AU - McGuffin, Peter

AU - Farmer, Anne

PY - 2009/11

Y1 - 2009/11

N2 - BACKGROUND: Being overweight or obese may be associated with poor response to antidepressants. The present report explores the moderation of antidepressant response by body weight to establish the specificity to antidepressant mode of action, type of depressive symptoms and gender.METHODS: Height and weight were measured in 797 men and women with major depression treated with escitalopram or nortriptyline for twelve weeks as part of the Genome Based Therapeutic Drugs for Depression (GENDEP) project. Body mass index (BMI) and obesity (BMI>30) were tested as predictors of change in depressive symptoms using mixed linear models.RESULTS: Higher BMI and obesity predicted poor response to nortriptyline but did not significantly influence response to escitalopram. The moderation of response by body weight was due to differential improvement in neurovegetative symptoms, including sleep and appetite. The relationship between body weight and change in neurovegetative symptoms was moderated by gender with obese men responding less to nortriptyline and obese women having poorer response to both antidepressants.LIMITATIONS: As no placebo arm was included, the specificity of findings to antidepressants is relative. Lack of specific measures precluded accounting for differences in body fat distribution.CONCLUSIONS: Body weight should be considered in the assessment of depression as it may inform the selection of antidepressant treatment.

AB - BACKGROUND: Being overweight or obese may be associated with poor response to antidepressants. The present report explores the moderation of antidepressant response by body weight to establish the specificity to antidepressant mode of action, type of depressive symptoms and gender.METHODS: Height and weight were measured in 797 men and women with major depression treated with escitalopram or nortriptyline for twelve weeks as part of the Genome Based Therapeutic Drugs for Depression (GENDEP) project. Body mass index (BMI) and obesity (BMI>30) were tested as predictors of change in depressive symptoms using mixed linear models.RESULTS: Higher BMI and obesity predicted poor response to nortriptyline but did not significantly influence response to escitalopram. The moderation of response by body weight was due to differential improvement in neurovegetative symptoms, including sleep and appetite. The relationship between body weight and change in neurovegetative symptoms was moderated by gender with obese men responding less to nortriptyline and obese women having poorer response to both antidepressants.LIMITATIONS: As no placebo arm was included, the specificity of findings to antidepressants is relative. Lack of specific measures precluded accounting for differences in body fat distribution.CONCLUSIONS: Body weight should be considered in the assessment of depression as it may inform the selection of antidepressant treatment.

KW - Adult

KW - Affect/drug effects

KW - Antidepressive Agents, Second-Generation/adverse effects

KW - Antidepressive Agents, Tricyclic/adverse effects

KW - Appetite/drug effects

KW - Body Mass Index

KW - Body Weight/physiology

KW - Citalopram/adverse effects

KW - Depressive Disorder, Major/drug therapy

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Nortriptyline/adverse effects

KW - Obesity/physiopathology

KW - Overweight/physiopathology

KW - Sleep/drug effects

KW - Treatment Outcome

U2 - 10.1016/j.jad.2009.02.013

DO - 10.1016/j.jad.2009.02.013

M3 - Article

C2 - 19269691

SN - 0165-0327

VL - 118

SP - 147

EP - 154

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

IS - 1-3

ER -

Body weight as a predictor of antidepressant efficacy in the GENDEP project

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this